



Anti-MMAE polyclonal antibody (CABT-B8997)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Target	Monomethyl auristatin E
Isotype	IgG
Source/Host	Mouse
Species Reactivity	N/A
Purification	Affinity Chromatography
Conjugate	Unconjugated
Applications	ELISA
Format	This antibody comes as 50x concentrated and is used in the MMAE-ADC competitive EIA
Size	100 µl
Buffer	0.01M PBS, 0.1%BSA, Proclin-300
Preservative	None
Storage	-20°C (-80°C for long term)

BACKGROUND

Introduction	Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and
--------------	---

in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer. MMAE is actually desmethyl-auristatin E; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin E itself.

Keywords

Monomethyl auristatin E
